The US Food and Drug Administration (FDA) has approved a gene therapy from Rocket Pharmaceuticals to treat a rare immune disorder. This therapy, the name of which is not mentioned in the article, was tested on a small group of nine patients. The testing yielded positive results. This is an important step in the treatment of this rare disease. FDA approval allows the commercial use of this gene therapy for patients with a given immune disorder.